Tyme Technologies (TYME) Stock Analysis

What Tyme Technologies does

Tyme Technologies, Inc. is a biopharmaceutical firm dedicated to developing cancer metabolism-based therapies (CMBTs) within the United States. Its flagship therapeutic candidate, SM-88, is currently undergoing Phase II/III clinical evaluation across 15 distinct cancer types, including but not limited to pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company's pipeline also includes TYME-19, an orally administered synthetic bile acid derivative in preclinical stages for combating SARS-CoV-2 infections, and TYME-18, another preclinical CMBT compound designed to treat tumors that are inoperable. Tyme Technologies maintains research partnerships, notably with the Mayo Clinic for comprehensive analysis of SM-88's impact on pancreatic cancer cell gene expression, epigenetics, and metabolic changes, and with a research investigator at Georgetown University to study SM-88's effects in breast cancer. Founded in 2011 as Global Group Enterprises Corp. and headquartered in Bedminster, New Jersey, Tyme Technologies, Inc. has been operating as a subsidiary of Syros Pharmaceuticals, Inc. since September 16, 2022.

Key metrics

ETFs linked to TYME

Broad-market and Healthcare sector ETFs an investor holding Tyme Technologies is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TYME fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Tyme Technologies?

Tyme Technologies trades under the ticker TYME on NASDAQ.

Which exchange is TYME listed on?

TYME is listed on NASDAQ.

What sector does Tyme Technologies operate in?

Tyme Technologies is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TYME in a portfolio?

PortView shows TYME's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.